[Federal Register Volume 87, Number 7 (Tuesday, January 11, 2022)]
[Notices]
[Page 1435]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00326]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-942]


Bulk Manufacturer of Controlled Substances Application: Johnson 
Matthey, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Johnson Matthey, Inc., has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substance(s). Refer to 
Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before March 14, 2022. 
Such persons may also file a written request for a hearing on the 
application on or before March 14, 2022.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on November 2, 2021, Johnson Matthey, Inc., 2003 Nolte 
Drive West Deptford, New Jersey 08066-1742, applied to be registered as 
a bulk manufacturer of the following basic class(es) of controlled 
substance(s):

------------------------------------------------------------------------
                                            Drug
          Controlled Substance              Code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid...............     2010  I
Marihuana...............................     7360  I
Tetrahydrocannabinols...................     7370  I
Noroxymorphone..........................     9145  I
Difenoxin...............................     9168  I
Amphetamine.............................     1100  II
Methamphetamine.........................     1105  II
Lisdexamfetamine........................     1205  II
Methylphenidate.........................     1724  II
Nabilone................................     7379  II
4-Anilino-N-Phenethyl-4-Piperidine           8333  II
 (ANPP).
Norfentanyl.............................     8366  II
Cocaine.................................     9041  II
Codeine.................................     9050  II
Dihydrocodeine..........................     9120  II
Oxycodone...............................     9143  II
Hydromorphone...........................     9150  II
Diphenoxylate...........................     9170  II
Ecgonine................................     9180  II
Hydrocodone.............................     9193  II
Levorphanol.............................     9220  II
Meperidine..............................     9230  II
Methadone...............................     9250  II
Methadone intermediate..................     9254  II
Morphine................................     9300  II
Thebaine................................     9333  II
Opium tincture..........................     9630  II
Oxymorphone.............................     9652  II
Noroxymorphone..........................     9668  II
Alfentanil..............................     9737  II
Remifentanil............................     9739  II
Sufentanil..............................     9740  II
Tapentadol..............................     9780  II
Fentanyl................................     9801  II
------------------------------------------------------------------------

    The company plans to bulk manufacture the listed controlled 
substances for the internal use intermediates or for sale to its 
customers. In reference to drug codes 7360 (Marihuana), and 7370 
(Tetrahydrocannabinols), the company plans to bulk manufacture these 
drugs as synthetic. The company plans to bulk manufacture for either 
internal usage as intermediates or to sale to customers as Active 
Pharmaceutical Ingredients (API). No other activities for these drug 
codes are authorized for this registration.

Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2022-00326 Filed 1-10-22; 8:45 am]
BILLING CODE P